Empowering impact across life sciences

MINERVIQ helps life sciences startups and pharmaceutical companies connect, collaborate, and grow — through digital innovation, strategic data expertise, and deep industry insight.

About

We build the bridges life sciences innovation depends on.
MINERVIQ is a boutique consulting firm specializing in the life sciences sector. We operate at the intersection of biotech, pharma, and digital transformation — enabling strategic partnerships, data-driven decision-making, and impact. Whether you’re an early-stage biotech preparing to scale, or a pharma company seeking innovation, we help you connect, align, and accelerate. MINERVIQ was founded by Dr. John Reinhard Pietzsch, who is an immunologist, data science leader, and pharmaceutical strategist whose career bridges groundbreaking academic research and high-impact roles in the biopharmaceutical industry.

Our Values

Specialized Focus 

We exclusively serve the life sciences sector, offering tailored expertise in biotech, pharma, and health tech innovation.

Client-Centric Approach

We build lasting partnerships by delivering bespoke solutions, working closely with clients at every step to ensure measurable impact.

Deep Domain Expertise

We hold extensive knowledge, experience and understanding within the life sciences, to provide insightful and actionable advice. 

Agility and Flexibility

We move fast, adapt to evolving needs, and deliver results that create long-term customer value.

What we offer

Strategic Connection: Startup Enablement & Partner Readiness

“Where Connection becomes Partnership, and Partnership drives Value.”

We support biotech startups in becoming truly “pharma-ready” – strategically, operationally, and digitally. MINERVIQ works with early- and growth-stage companies to refine their value proposition, align their data and regulatory strategies, and position themselves for successful partnerships, licensing, or investment. We offer deep insight into what pharma looks for and help you build the assets, infrastructure, and narrative needed to scale.

  • Strategic positioning for licensing, co-development, or partnerships
  • Partner readiness audits (regulatory, digital, and data maturity)
  • Investor and partner-facing materials: pitch decks, data rooms, and narratives
  • Identifying funding opportunities and grant writing
  • Pharma scouting, startup evaluation, and onboard support

There’s a booming trend of large pharma turning to early-stage biotech for innovation. And vice versa for early-stage biotech to scale. But the “connection layer” is often fragmented. We streamline that bridge.

Digital & Data Excellence: Systems, platforms, and data infrastructure

“Where Data becomes Insight, and Insight drives Impact.”

We help life sciences organizations unlock the full potential of their data and future-proof operations with scalable digital strategies. By implementing fit-for-purpose data frameworks, we ensure that information is structured, governed, and primed for insight generation across partners and platforms. Our expertise spans from identifying high-value use cases and data sources to building data-driven business models, that enable you to turn raw data into strategic assets that fuel scientific, regulatory, and commercial decisions.

  • Digital strategy assessment and refinement
  • Data framework development
  • AI readiness and use case development
  • Data mapping and sourcing enablement (e.g., RWD, omics, digital biomarkers, image data)
  • Business model design for data monetization

Data is a core asset and value driver in life sciences. To compete, organizations must enable seamless data sharing, reduce development costs, and accelerate timelines — all while staying compliant.  We help you do so with foresight.

Impact-first approach: General Business Consulting services

“Where Intelligence becomes Strategy, and Strategy drives Results.”

Our General Business Consulting services support life sciences organizations in navigating complex business challenges and achieving ambitious goals. We serve companies to refine strategic direction, optimize organizational structures, and improve operational efficiency. Whether you’re launching a new venture, entering new markets, or undergoing a merger or acquisition, we provide expert guidance on business planning, change management, and performance improvement. 

  • Strategic planning and roadmapping 
  • Organizational design and scaling strategies 
  • Operational efficiency and process improvement
  • Business model innovation and go-to-market strategies
  • Change management and organizational readiness enablement

In today’s dynamic life sciences landscape, organizations face increasing pressure to innovate, adapt, and grow – all while managing uncertainty and regulatory complexity. We help you adapt quickly with clarity, speed, and confidence.

Who We Help

Pharma & Biopharma

Access cutting-edge innovation with confidence, speed, and clarity

Startups & Biotechs


Ready your platform, process, and data for partnering or scaling

Investors & Accelerators

Evaluate readiness, reduce risk, and guide portfolio companies

Get in Touch

Let’s explore how MINERVIQ can help you to: 


Build smarter bridges between science and scale

Drive impact with Data and Digital

Drive results for your customers and patients 

Leadership

Dr. John Reinhard Pietzsch

Founder and CEO

John is an immunologist, data science leader, and pharmaceutical strategist whose career bridges groundbreaking academic research and high-impact roles in the biopharmaceutical industry. He holds a Diplom in Biochemistry and a Ph.D. in Immunology (Dr. rer. nat., summa cum laude) from Freie Universität Berlin, where his doctoral research focused on the characterization of human anti-HIV-1 Env-specific monoclonal antibodies in vitro and in vivo. His scientific contributions have been instrumental in identifying novel epitopes on the HIV envelope protein and in developing a transgenic mouse model for HIV-1 entry, advancing our understanding of broadly neutralizing antibodies and their therapeutic potential. His work has been published in leading scientific journals helping to shape global vaccine design and antibody-based strategies.
Following his academic career, John transitioned into the pharmaceutical industry, where he served as Senior Director and Head of Data Science and Insights at Bayer Pharmaceuticals. In this role, he led global AI-driven programs focusing on patient safety and medical sciences. His leadership also extended to Business Consulting, Medical Affairs, and Radiology, where he helped shape global strategies and digital transformation initiatives. Particularly, these included developing a Pharma research strategy, post-merger integration planning, reorganizational change management, business model development, and due diligences. He further advanced his leadership and management practice as part of Bayer’s executive education program at IMD Business School and MIT Sloan School of Management.  Drawing on a rare combination of scientific rigor, business acumen, and data fluency, he also advises Biotech startups in strategic planning, innovation management, and business development.  Based in the Berlin metropolitan area, John is widely recognized for uniting cross-functional perspectives from academia, biotech, and industry to drive forward-thinking innovation and meaningful transformation in life sciences and global health.
Following his academic career, John transitioned into the pharmaceutical industry, where he served as Senior Director and Head of Data Science and Insights at Bayer Pharmaceuticals. In this role, he led global AI-driven programs focusing on patient safety and medical sciences. His leadership also extended to Business Consulting, Medical Affairs, and Radiology, where he helped shape global strategies and digital transformation initiatives. Particularly, these included developing a Pharma research strategy, post-merger integration planning, reorganizational change management, business model development, and due diligences. He further advanced his leadership and management practice as part of Bayer’s executive education program at IMD Business School and MIT Sloan School of Management.  Drawing on a rare combination of scientific rigor, business acumen, and data fluency, he also advises Biotech startups in strategic planning, innovation management, and business development.  Based in the Berlin metropolitan area, John is widely recognized for uniting cross-functional perspectives from academia, biotech, and industry to drive forward-thinking innovation and meaningful transformation in life sciences and global health.